This is a single-center, randomized controlled, parallel, non-inferiority trial. All adult patients with benign gallbladder disease with an indication for cholecystectomy will be assessed for eligibility and included after obtaining informed consent. A total of 276 patients will be randomized to undergo either robotic cholecystectomy (RC) or laparoscopic cholecystectomy (LC). The primary endpoint will be the incidence and severity of postoperative complications within 30 days after surgery. Secondary endpoints include perioperative outcomes, total health care utilization, health-related quality of life (HR-QoL) as assessed by patient-reported outcome measures, and cost-effectiveness. Follow-up assessments will be conducted at 7 and 30 days postoperatively. This is the first randomized controlled trial designed to compare RC with LC in the treatment of benign gallbladder disease. The trial aims to evaluate the safety and non-inferiority of RC relative to LC, providing important evidence to guide the progress and adoption of robotic surgery in clinical practice.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence (%) of postoperative complications within 30 days after surgery
Timeframe: From day of surgery up to 30 days postoperatively
Severity of postoperative complications within 30 days after surgery
Timeframe: From day of surgery up to 30 days postoperatively
Frequency (%) of postoperative complications within 30 days postoperatively
Timeframe: From day of surgery up to 30 days postoperatively
Comprehensive Complication Index (CCI) score within 30 days after surgery
Timeframe: From day of surgery up to 30 days postoperatively